volume 4, issue 1, P24-34 2011
DOI: 10.15283/ijsc.2011.4.1.24
View full text
Sign up to set email alerts

Abstract: To date, studies on the application of mesodermally derived mesenchymal-, hematopoietic-and vascular-lineage cells for cell therapy have provided either poor or insufficient data. The results are equivocal with regard to therapeutic efficiency and yield. Since the establishment of human embryonic stem cells (hESCs) in 1998, the capacity of hESCs to differentiate into various mesodermal lineages has sparked considerable interest in the regenerative medicine community, a group interested in generating specializ…

Expand abstract